AI Article Synopsis

  • The study investigated the relationship between Human Papilloma Virus (HPV) and oropharyngeal cancers (OPCs) in tobacco users, assessing how HPV status impacts treatment outcomes in 212 patients with advanced non-metastatic squamous cell carcinoma.
  • Among the 177 patients with available biopsy samples, only 13% tested positive for p16, a marker for HPV infection, and a significant link was found between chewable tobacco use and HPV positivity.
  • Results showed that HPV+ patients had better survival rates (5-year Overall Survival: 43.4%) and local control compared to HPV- patients, highlighting the potential benefits of routine p16 testing in clinical practice despite the lower prevalence of HPV in the Indian population.*

Article Abstract

To find if an association could be established between Human Papilloma Virus (HPV) infection and oropharyngeal cancers (OPCs) in a group of patients known to be regular users of tobacco, and to determine the impact of HPV status on clinical outcomes.Case records of 212 patients with AJCC-7 (The American Joint Committee on Cancer 7th edition) stages II-IVB non metastatic squamous cell carcinoma of the oropharynx treated using radical radiotherapy with or without chemotherapy during the years 2015-2018 were retrieved. Formalin-fixed, paraffin-embedded blocks from oropharyngeal biopsies were available for 177 patients and were evaluated for p16 expression by immunohistochemical (IHC) staining. More than 50% nuclear staining with or without cytoplasmic staining was considered HPV+ . The association between tobacco use and HPV, as well as the influence of HPV status on survival outcomes were assessed. p16 expression was found to be positive in 23(13%) patients. Significant association was found between chewable tobacco usage and HPV positivity ( = 0.051). The median follow up was 20.5 months (range: 3-80). 5-year Overall Survival was 43.4% and 29.8% ( = 0.044) in HPV+ and HPV- patients, respectively. Local control was significantly better in HPV+ patients (38.6% vs. 25.3%,  = 0.049). There was also a trend towards improved Disease-free Survival in HPV+ patients (31 months vs. 15 months,  = 0.078). Though less in prevalence among the Indian population, improved outcomes in HPV+ OPC patients and widely available IHC HPV assays signifies the routine implementation of p16 testing in day-to-day clinical practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895501PMC
http://dx.doi.org/10.1007/s12070-021-02427-wDOI Listing

Publication Analysis

Top Keywords

hpv infection
8
assessed p16
8
tobacco usage
8
oropharyngeal cancers
8
patients
8
hpv status
8
p16 expression
8
hpv+ patients
8
hpv
6
prognostic hpv
4

Similar Publications

Background/objectives: Human papillomavirus (HPV) is the primary cause of high-grade cervical lesions and cervical cancer worldwide. In Norway, HPV vaccination was introduced in 2009 for seventh-grade girls and extended through a catch-up program from 2016 to 2019 for women born between 1991 and 1996. This study evaluates the impact of the catch-up vaccination program on the incidence of HPV and high-grade cervical lesions in Troms and Finnmark.

View Article and Find Full Text PDF

Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines.

Vaccines (Basel)

January 2025

Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing 400030, China.

Human papillomavirus (HPV) is a major global health issue and is recognized as the leading cause of cervical cancer. While prophylactic vaccination programs have led to substantial reductions in both HPV infection rates and cervical cancer incidence, considerable burdens of HPV-related diseases persist, particularly in developing countries with inadequate vaccine coverage and uptake. The development of therapeutic vaccines for HPV represents an emerging strategy that has the potential to bolster the fight against cervical cancer.

View Article and Find Full Text PDF

Developing an Effective Therapeutic HPV Vaccine to Eradicate Large Tumors by Genetically Fusing Xcl1 and Incorporating IL-9 as Molecular Adjuvants.

Vaccines (Basel)

January 2025

State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China.

Background: Human papillomavirus (HPV) is a prevalent infection affecting both men and women, leading to various cytological lesions. Therapeutic vaccines mount a HPV-specific CD8+ cytotoxic T lymphocyte response, thus clearing HPV-infected cells. However, no therapeutic vaccines targeting HPV are currently approved for clinical treatment due to limited efficacy.

View Article and Find Full Text PDF

Background/objectives: Adequate knowledge and correct attitudes about the HPV vaccine influence awareness of the importance of preventing HPV-related diseases, which is particularly important for future healthcare professionals. We aim to examine the share of correct answers and the prevalence of different attitudes about the HPV vaccine among active regular students of the Faculty of Medicine in Novi Sad.

Methods: A cross-sectional study was conducted from 1 to 30 November 2023 using a structured survey questionnaire.

View Article and Find Full Text PDF

Cervical intraepithelial neoplasia (CIN) is a premalignant cervical condition closely linked to persistent high-risk HPV infection, a major risk factor for cervical cancer. This study aims to investigate the relationship between cervicovaginal infections, HPV infection, and CIN development in 94 Romanian women with cervical lesions. Comprehensive assessments included HPV genotyping, cytology, colposcopy, and histopathology.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!